New hope for rare cancers: drug duo shows promise
NCT ID NCT03074513
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the combination helps control the disease better than historical treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atezolizumab and bevacizumab (immunotherapy and anti-angiogenic drugs)
- What this could lead to
- If it works, this could offer a new treatment option for people with rare solid tumors that are hard to treat.
- What could go wrong
- This is a mid-stage trial with no control group, so results are uncertain. Side effects from immunotherapy and bleeding risks from bevacizumab are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APPENDIX ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Do Younger-Age pancreatic tumors behave differently? a new study digs in
- Can adding radiation boost the power of immunotherapy in advanced cervical cancer?
- Can a black seed extract boost immunotherapy against a rare cancer?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- New drug cocktail aims to fight rare cancer